Nouscom
Clinical-stage biotechnology company developing next-generation neoantigen-targeted immunotherapies.
Nouscom is a biotech & life sciences company based in Basel, CH, founded in 2015. It has raised $135.04 million in disclosed funding. Its latest round was a Series D of €120 million in October 2026.
Overview
No overview yet. It is written from sources once there are enough of them.
Funding
Total disclosed: $135M across 1 round. Computed only from sourced rounds.
Investors
In the news
Questions and answers
What does Nouscom do?
Clinical-stage biotechnology company developing next-generation neoantigen-targeted immunotherapies.
How much has Nouscom raised?
Nouscom has raised $135.04 million in disclosed funding across 1 round tracked by OSH.
Who has invested in Nouscom?
Investors in Nouscom include M Ventures, Revelation Partners, Angelini Ventures, EIB, Neva SGR and 9 more.
When and where was Nouscom founded?
Nouscom was founded in 2015 and is based in Basel, CH.
Timeline
Founded
Sources
- 1.Switzerland’s Nouscom bags €120 million to bring innovative cancer immunotherapy closer to clinical trials — EU-Startups, Oct 19, 2026